| Literature DB >> 30608678 |
Carson W Reed, Samantha E Yohn, Jordan P Washecheck, Hanna F Roenfanz, Marc C Quitalig, Vincent B Luscombe, Matthew T Jenkins, Alice L Rodriguez, Darren W Engers, Anna L Blobaum, P Jeffrey Conn1, Colleen M Niswender1, Craig W Lindsley.
Abstract
Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu7) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5× above the in vitro IC50 at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.Entities:
Year: 2019 PMID: 30608678 PMCID: PMC6501583 DOI: 10.1021/acs.jmedchem.8b01810
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446